GS-9451 is a potent macrocyclic HCV NS3 PI that achieved a median maximal change in HCV RNA of 3.6 log10 IU/mL (range, -4.7 log10 to -3.1 log10 IU/mL) following 3-day monotherapy in treatment-nave patients with HCV genotype 1 infection during phase I.
More Information Supplier PageGS-9451 is a potent macrocyclic HCV NS3 PI that achieved a median maximal change in HCV RNA of 3.6 log10 IU/mL (range, -4.7 log10 to -3.1 log10 IU/mL) following 3-day monotherapy in treatment-nave patients with HCV genotype 1 infection during phase I.
More Information Supplier PageGS-9451 is a potent macrocyclic HCV NS3 PI that achieved a median maximal change in HCV RNA of 3.6 log10 IU/mL (range, -4.7 log10 to -3.1 log10 IU/mL) following 3-day monotherapy in treatment-nave patients with HCV genotype 1 infection during phase I.
More Information Supplier PageL-779450 is a raf kinase inhibitor, a potential treatment for neurotraumatic diseases.
More Information Supplier PageL-779450 is a raf kinase inhibitor, a potential treatment for neurotraumatic diseases.
More Information Supplier PageL-779450 is a raf kinase inhibitor, a potential treatment for neurotraumatic diseases.
More Information Supplier PageL-779450 is a raf kinase inhibitor, a potential treatment for neurotraumatic diseases.
More Information Supplier PageNSC 663284 is a potent, cell-permeable, and irreversible inhibitor of all Cdc25 isoforms, with preference for Cdc25A (IC50 = 29, 95, and 89 nM for Cdc25A, Cdc25B2, and Cdc25C, respectively).
More Information Supplier Page
